Kaibao Pharmaceutical Co., Ltd. invested 95 million yuan to develop a new antidepressant drug, youxinding capsule, in cooperation with Shanghai Traditional Chinese medicine innovation and research center

On January 26, 2015, Shanghai Traditional Chinese Medicine Innovation Research Center (hereinafter referred to as "the center") and Shanghai Kaibao Pharmaceutical Co., Ltd (hereinafter referred to as "Shanghai Kaibao") officially signed the cooperation development agreement of "youxinding capsule" According to the provisions of the agreement, Shanghai Kaibao will contribute RMB 95 million to carry out the later clinical trial and research of youxinding capsule together with the center and share the rights and interests of the project Youxinding is the first national class 1 innovative drug in the field of neuropsychiatry in China, which has obtained clinical approval It is independently developed by the center and has independent intellectual property rights including its process and application patents Its patent scope covers China, the United States, Germany, France, the United Kingdom, Italy, Sweden, Japan and South Korea, etc The new drug has obtained the support of national major new drug creation projects during the 11th Five Year Plan and the 12th Five Year Plan The preparation of youxinding comes from the clinical antidepressant effect of traditional Chinese medicine ginseng, which is obtained from the metabolites of ginseng after oral administration In the production process, ginseng plants are used as raw materials to obtain a single compound with high purity through semi synthesis Preclinical trials showed that euxindine had high antidepressant activity and different mechanism from the existing antidepressants Euxindine can protect nerve cells and promote neurogenesis by activating Akt kinase system of nerve cells The mechanism of action is very consistent with the latest research on the pathogenesis of depression The phase I clinical trial of youxinding once again proved that the drug inherits the characteristics of ginseng traditional Chinese medicine with extremely low toxicity and side effects The phase IIa clinical trial of multicenter randomized double blind placebo control as dose exploration has been successfully completed The results showed that euxindine showed a good dose effect relationship in the main dose range, and the effect of the middle and high dose groups showed a better trend than that of the placebo group At the same time, no drug-related serious adverse events were found in each dose group (including the highest dose group), and the incidence of other adverse events was low and mild Experts in clinical trials at home and abroad and many experts in the field of psychotropic drugs in large international pharmaceutical enterprises believe that the dose-response relationship shown in the phase IIa clinical trial of euxindine shows that the middle and high dose groups have entered the effective dose range and reaffirmed the excellent safety of the drug, providing an important research basis and decision-making basis for the next clinical trial There is no doubt that once the development of euxindine is successful, a new "heavy bomb" will be born, and it is possible to make the patients with depression get rid of the existing clinical antidepressant drug side effects, and enter a new era of depression safety treatment Shanghai Kaibao said that the strategic R & D direction of youxinding capsule and the company's new drug reserve is completely the same, and this cooperation is conducive to the company's solution to the problem of single product; at the same time, the company's current main product, Tanreqing injection, has formed a marketing network and marketing model over the years, which is conducive to carrying the variety of "youxinding capsule", and then to play the company's marketing network The efficiency of the network is conducive to further forming the market scale Both sides are full of confidence and expectation for this cooperation.